Belpointe Asset Management’s Zivo Bioscience, Inc. Common Stock ZIVO Stock Holding History

Belpointe Asset Management’s Portfolio ZIVO Stock Details ZIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16	Closed	-$293	–	3631
2023 Q1	$293	Hold	16	–	–	﹤0.01%	3642
2022 Q4	$238	Buy	+16	New	+$279	﹤0.01%	3619

Other funds holding ZIVO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

VCA

Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return

Bartlett & Co Cincinnati, Ohio $6.16B AUM 20.29% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Belpointe Asset Management's ZIVO Position: Q2 2023 in Review

Belpointe Asset Management sold out of Zivo Bioscience, Inc. Common Stock (ZIVO) in Q2 2023, closing a stake of 16 shares — an estimated $293 sold.

Belpointe Asset Management first reported a position in ZIVO in Q4 2022 and held it in 2 quarters. The position peaked at $293 in Q1 2023. 12 funds tracked by Wall St. Rank hold ZIVO as of Q2 2023.

Belpointe Asset Management reported no remaining Zivo Bioscience, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Belpointe Asset Management sold 16 Zivo Bioscience, Inc. Common Stock shares in Q2 2023, an estimated $293.
Belpointe Asset Management first reported a position in Zivo Bioscience, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Belpointe Asset Management's Zivo Bioscience, Inc. Common Stock position peaked at $293 in Q1 2023.
12 funds tracked by Wall St. Rank held Zivo Bioscience, Inc. Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.